GB001

DRUG2 trials

Sponsors

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.

Conditions

AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 2

GB001 in Adult Subjects With Moderate to Severe Asthma

CompletedNCT03683576

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.Asthma

Start: 2018-10-22End: 2020-08-18Updated: 2021-09-16

GB001 in Adult Participants With Chronic Rhinosinusitis

CompletedNCT03956862

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Start: 2019-05-16End: 2020-08-05Updated: 2021-08-23

Related Papers

Results of a Phase 2b Trial With GB001, a Prostaglandin D<sub>2</sub> Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.

2022-03-037 citations

GB001 potently inhibits PGD2 metabolite-induced DP2-mediated cell signaling and eosinophil activation

2020-09-071 citations

GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects

2020-09-07

GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects

2020-09-07